Navigation Links
DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
Date:4/1/2008

EL SEGUNDO, Calif., April 1, 2008 /PRNewswire/ -- DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney failure and disease, today announced its former Chief Medical Officer (CMO) Charles J. McAllister, M.D. will retire effective April 1, 2008. Dr. McAllister stepped down as CMO in July 2007, and has since served as CMO emeritus in the Office of the CMO.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

"Charlie has provided 30 years of incredible service to kidney care patients and the broader kidney care community, as a practicing nephrologist, as a hospital chief of staff and as DaVita's chief medical officer," said DaVita CEO Kent Thiry. "The combination of his energy, his intellect, his sense of humor and his warm bedside manner is amazing."

Dr. McAllister served as CMO for DaVita(R) since 2000. During that time, his dedication to continuous improvement in the areas of physician performance management, national clinical measurement development, product evaluation and testing, and clinical compliance program implementation, among others, helped DaVita become a national leader in clinical outcomes. Dr. McAllister's efforts also helped shaped DaVita's community-like work environment, which has been broadly written about and is taught at many major business schools.

"Dr. McAllister really represents the life-force of the Physician Council at DaVita, serving as DaVita's physician beacon of outstanding and compassionate care for our most vulnerable patients," said John Robertson, M.D. "All of the physicians remaining with the Office of the Chief Medical Officer will continue to aspire to the same level of professionalism and integrity that Charlie single handedly inspired since the day he joined with DaVita."

Prior to serving as CMO for DaVita, Dr. McAllister served as vice president of medical affairs for Gambro and Vivra, respectively. He also spent more than 20 years as medical director of dialysis facilities in the Tampa Bay area, where as one of the first practicing local nephrologists, he created dialysis programs serving a community of more than one million people.

"Of my major accomplishments, I'm especially proud of being given the honor to work with many colleagues, nurses, dieticians and others -- I was able to learn from them all," said Dr. McAllister. "As I retire from my executive career, I plan on working in the not-for-profit sector with the disadvantaged and underserved. I'm actually looking forward to putting back on my white coat and stethoscope."

Dr. McAllister has accepted a part-time position as medical director with Bay Area Treatment Center in Pinellas Park, Fla., where he will work with individuals suffering from substance dependence.

The Office of the CMO replaced the position of DaVita CMO on July 1, 2007. Membership comprises John Robertson, M.D., David Van Wyck, M.D. and Robert Provenzano, M.D.; and Allen Nissenson, M.D. serves as Special Advisor to the Office of the CMO.

DaVita is a registered trademark of DaVita Inc. All other trademarks are the property of their respective owners.

About DaVita Inc.

DaVita Inc., a FORTUNE 500(R) company, is a leading provider of kidney care in the United States, providing dialysis services and education for patients with chronic kidney failure and end stage renal disease. DaVita manages over 1,300 outpatient facilities and acute units in over 700 hospitals located in 43 states and the District of Columbia, serving approximately 107,000 patients. For more information, please visit http://www.davita.com.


'/>"/>
SOURCE DaVita Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NxStage Medical Announces Needle Supply Agreement with DaVita
2. DaVita to Present at UBS Best of Americas Conference
3. Human Pheromone Sciences Announces Quarterly and Full Year Results
4. Dragon Pharma announces 2007 full year financial results
5. Genaera Corporation Announces 2007 Financial Results
6. Genmab Announces Year End 2007 Financial Results
7. Immunosyn Corporation Announces 2007 Results, Files 10KSB
8. Elbit Imaging Ltd. Announces Results For Fiscal Year 2007
9. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
10. China Pharma Holdings, Inc. Announces Record 2007 Year End Results
11. Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016  Spherix Incorporated (Nasdaq: SPEX ) -- an ... monetization of intellectual property, today provided an update on ... Northern District of Texas and ... Inter Partes Re-examination ("IPR") proceedings that VTech ... IPR was initiated on only certain claims of two ...
(Date:2/4/2016)... 4, 2016 Strasbourg, France ... --> Strasbourg, France , to the ... PharmaVentures is pleased to announce that it acted as an ... unit in Strasbourg, France , to the ... --> --> Transgene (Euronext: TNG), a member ...
(Date:2/3/2016)... Pa. , Feb. 3, 2016  Discovery ... company focused on developing aerosolized KL4 surfactant therapies ... of Directors has approved an inducement award as ... Fraser , its newly appointed President and Chief ... Board,s Compensation Committee on February 1, 2016 and ...
(Date:2/3/2016)... and HOLLISTON, Mass., Feb. 3, 2016 Harvard ... a biotechnology company developing bioengineered organ implants for ... today announced that CEO Jim McGorry , ... Investor Conference on Tuesday, February 9, 2016 ... York City . HART,s presentation will be ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 Technology Enhancements Accelerate Growth of X-ray Imaging ... digital and computed radiography markets in Thailand ... Indonesia (TIM). It provides an in-depth ... well as regional market drivers and restraints. The study ... and market attractiveness, both for digital and computed radiography. ...
(Date:2/1/2016)... , February 1, 2016 Rising ... to drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new ... market size through 2020   ... coupled with new technological advancements to drive global touchfree ...
(Date:1/28/2016)... SYNA ), a leading developer of human interface solutions, today ... --> --> Net revenue ... to the comparable quarter last year to $470.5 million. Net income ... $0.93 per diluted share. --> ... 2016 grew 9 percent over the prior year period to $60.3 ...
Breaking Biology News(10 mins):